Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
5,028.73 -42.90 (-0.85%) Dow
37,989.25 -471.67 (-1.23%) Nasdaq
15,518.70 -194.05 (-1.23%) Bitcoin USD
64,157.57 -507.04 (-0.78%) CMC Crypto 200
1,387.81 +5.24 (+0.38%)
Vertex Pharmaceuticals Incorporated (0QZU.L)
| Previous close | 401.33 |
| Open | 402.67 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 393.37 - 404.62 |
| 52-week range | 290.87 - 446.29 |
| Volume | |
| Avg. volume | 2,907 |
| Market cap | 1.013B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 0.42 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- CNW Group
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex's cell therapies for type 1 diabetes (T1D). TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies.
- Business Wire
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
BOSTON, April 18, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548).
- Business Wire
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
BOSTON & SEATTLE, April 10, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Director
